Pliant Therapeutics Advances in Clinical Trials and Oncology Research: A Promising Outlook for PLRX Stock

Pliant Therapeutics (PLRX) is advancing in clinical trials and oncology research, with key data from the BEACON-IPF trial expected in Q1. The company has also reported promising antitumor effects in a Phase 1 dose escalation study of PLN-101095. Analysts forecast an average target price of $4.79, with a high estimate of $17.00 and a low estimate of $1.50, indicating a potential upside of 227.79% from the current price of $1.46. The average brokerage recommendation is currently 2.8, indicating a "Hold" status.